{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-23-000095","form_type":"8-K","ticker":"CFOR","cik":"0001293818","company_name":"CapForce Inc.","filed_at":"2023-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.258497+00:00","generated_at":"2026-06-20T13:48:49.657760+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OpGen reports preliminary 2022 revenue of $2.7M, within guidance; cash $7.4M; raises $7.5M in offering","bullets":["Preliminary full-year 2022 revenue approximately $2.7M, within most recent guidance range.","Cash position as of Dec 31, 2022: $7.4M; closed public offering on Jan 11, 2023 with gross proceeds $7.5M.","Implemented 1-for-20 reverse stock split to regain Nasdaq minimum bid price compliance.","UTI clinical trial achieved 96.4% sensitivity and 97.4% specificity; preparing FDA submission.","Signed second Acuitas AMR Gene Panel customer contract and installed first two systems."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-23-000095","json":"https://secwatch.observer/filing/0001079973-23-000095.json","markdown":"https://secwatch.observer/filing/0001079973-23-000095.md","text":"https://secwatch.observer/filing/0001079973-23-000095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323000095/0001079973-23-000095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323000095/opgen_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T13:48:49.657760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f86659c88a35f066026ad76f0a6c48320feb5941","claim":"CapForce Inc. reported year ended December 31, 2022 results: revenue approximately $2.7 million.","evidence_excerpt":"Preliminary revenue for full year 2022 was approximately $2.7 million, which falls within the most recent guidance range the Company had provided in its Q3 earnings call.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323000095/0001079973-23-000095-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Revenue","value":"approximately $2.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}